MX9304501A - Quimioterapia para cancer. - Google Patents
Quimioterapia para cancer.Info
- Publication number
- MX9304501A MX9304501A MX9304501A MX9304501A MX9304501A MX 9304501 A MX9304501 A MX 9304501A MX 9304501 A MX9304501 A MX 9304501A MX 9304501 A MX9304501 A MX 9304501A MX 9304501 A MX9304501 A MX 9304501A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty acid
- fas
- cells
- acid synthesis
- chemotherapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
Abstract
La sintasa de ácido graso (FAS) se sobreexpresa en carcinomas con mala prognosis, pero se identifica poca expresión de FAS en los tejidos normales. La inhibición de la actividad de FAS es selectivamente tóxica para las células de carcinoma, mientras que las células normales con baja actividad de FAS son resistentes. La presente invención proporciona un método para el tratamiento de pacientes de cáncer donde se inhibe la síntesis de Acido graso mediante la células del tumor del paciente, con una interrupción resultante del proceso de la enfermedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91771692A | 1992-07-24 | 1992-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9304501A true MX9304501A (es) | 1994-04-29 |
Family
ID=25439227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9304501A MX9304501A (es) | 1992-07-24 | 1993-07-26 | Quimioterapia para cancer. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0651636B1 (es) |
JP (1) | JPH07509470A (es) |
KR (2) | KR100325766B1 (es) |
AT (1) | ATE225167T1 (es) |
AU (1) | AU682007B2 (es) |
CA (1) | CA2140866C (es) |
DE (1) | DE69332353T2 (es) |
DK (1) | DK0651636T3 (es) |
ES (1) | ES2183815T3 (es) |
MX (1) | MX9304501A (es) |
PT (1) | PT651636E (es) |
WO (1) | WO1994002108A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614551A (en) * | 1994-01-24 | 1997-03-25 | The Johns Hopkins University | Inhibitors of fatty acid synthesis as antimicrobial agents |
US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
AU7668596A (en) * | 1995-11-17 | 1997-06-11 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
EP1374875A3 (en) | 1997-10-15 | 2004-01-07 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome |
JP2001522799A (ja) | 1997-11-10 | 2001-11-20 | メモリアル スローン−ケタリング キャンサー センター | 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法 |
CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
KR20090031957A (ko) * | 1999-11-12 | 2009-03-30 | 더 존스 홉킨스 유니버시티 | 세포내 말로닐 CoA의 수준을 증가시킴에 의한 암의 치료방법 |
US7427689B2 (en) | 2000-07-28 | 2008-09-23 | Georgetown University | ErbB-2 selective small molecule kinase inhibitors |
WO2002089847A1 (en) * | 2001-02-15 | 2002-11-14 | The Johns Hopkins University School Of Medicine | Cytostatic effects of fatty acid synthase inhibition |
US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
AU2002360335A1 (en) | 2001-11-01 | 2003-05-12 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at bcl-2 |
CA2503717A1 (en) * | 2002-10-31 | 2004-05-21 | Fasgen Llc | A method for inhibiting cancer development by fatty acid synthase inhibitors |
EP2633856A3 (en) * | 2003-05-09 | 2014-01-01 | The Trustees of The University of Pennsylvania | ATP citrate lyase inhibitors for treating cancer |
SG151299A1 (en) | 2004-03-25 | 2009-04-30 | Univ Michigan | Gossypol co-crystals and the use thereof |
CA2575367A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
WO2007117038A1 (ja) * | 2006-04-07 | 2007-10-18 | Japanese Foundation For Cancer Research | 癌の予防・治療剤 |
US8729239B2 (en) | 2009-04-09 | 2014-05-20 | Nuclea Biotechnologies, Inc. | Antibodies against fatty acid synthase |
EP2993980B1 (en) * | 2013-05-10 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Lipid scavenging in ras cancers |
KR102136643B1 (ko) | 2018-12-04 | 2020-07-22 | 재단법인대구경북과학기술원 | 신규한 간암 진단 마커 및 이의 용도 |
US20220408724A1 (en) * | 2019-11-25 | 2022-12-29 | Kao Corporation | Method for controlling metabolism of branched fatty acid |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4328246A (en) * | 1979-08-14 | 1982-05-04 | Joseph Gold | Anti Walker 256 carcinoma agent and combination thereof |
JPS59225115A (ja) * | 1983-06-06 | 1984-12-18 | Ota Seiyaku Kk | 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル |
JPS6058917A (ja) * | 1983-09-09 | 1985-04-05 | Rikagaku Kenkyusho | 制癌剤 |
GB8607137D0 (en) * | 1986-03-21 | 1986-04-30 | Efamol Ltd | Compositions |
DD252616B1 (de) * | 1986-09-08 | 1990-06-20 | Adw Ddr | Verfahren zur herstellung von cerulenin auf mikrobiologischem wege |
JPH01132542A (ja) * | 1987-11-19 | 1989-05-25 | Toomen:Kk | ゴッシポールラセミ体の光学分割法 |
JPH02113850A (ja) * | 1988-10-21 | 1990-04-26 | Nippon Oil & Fats Co Ltd | 発癌抑制用油脂組成物 |
JPH02247125A (ja) * | 1989-03-17 | 1990-10-02 | Koken Kk | 悪性腫瘍細胞増殖抑制剤 |
-
1993
- 1993-07-26 MX MX9304501A patent/MX9304501A/es not_active IP Right Cessation
- 1993-07-26 PT PT93918397T patent/PT651636E/pt unknown
- 1993-07-26 KR KR1019950700317A patent/KR100325766B1/ko not_active IP Right Cessation
- 1993-07-26 DK DK93918397T patent/DK0651636T3/da active
- 1993-07-26 KR KR1020017009035A patent/KR100329245B1/ko not_active IP Right Cessation
- 1993-07-26 DE DE69332353T patent/DE69332353T2/de not_active Expired - Fee Related
- 1993-07-26 AT AT93918397T patent/ATE225167T1/de not_active IP Right Cessation
- 1993-07-26 ES ES93918397T patent/ES2183815T3/es not_active Expired - Lifetime
- 1993-07-26 WO PCT/US1993/007023 patent/WO1994002108A1/en active IP Right Grant
- 1993-07-26 CA CA002140866A patent/CA2140866C/en not_active Expired - Fee Related
- 1993-07-26 JP JP6504755A patent/JPH07509470A/ja active Pending
- 1993-07-26 AU AU47864/93A patent/AU682007B2/en not_active Ceased
- 1993-07-26 EP EP93918397A patent/EP0651636B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1994002108A1 (en) | 1994-02-03 |
EP0651636A1 (en) | 1995-05-10 |
AU4786493A (en) | 1994-02-14 |
CA2140866C (en) | 2003-05-27 |
EP0651636B1 (en) | 2002-10-02 |
DE69332353T2 (de) | 2003-07-10 |
DE69332353D1 (de) | 2002-11-07 |
ES2183815T3 (es) | 2003-04-01 |
KR100325766B1 (ko) | 2002-07-27 |
PT651636E (pt) | 2003-02-28 |
ATE225167T1 (de) | 2002-10-15 |
AU682007B2 (en) | 1997-09-18 |
KR100329245B1 (ko) | 2002-03-18 |
DK0651636T3 (da) | 2003-01-27 |
CA2140866A1 (en) | 1994-02-03 |
JPH07509470A (ja) | 1995-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9304501A (es) | Quimioterapia para cancer. | |
Vonderheid et al. | A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy | |
DK0738107T3 (da) | Inhibitorer for fedtsyresyntese som antimikrobielle midler | |
NO990066L (no) | Apoptose-induserende adamantylderivater og deres anvendelse som anticancer-midler | |
IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
HUP0000558A2 (hu) | Aktív D-vitamin analógok alkalmazása prosztatabetegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
MX9804009A (es) | Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. | |
AU1195499A (en) | Thyroxine analogues having no significant hormonal activity to treat malignant tumors | |
IL127384A0 (en) | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity | |
CA2337205A1 (en) | Treatment of skin disorders | |
WO2002039999B1 (en) | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition | |
ATE406160T1 (de) | Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs | |
BR9808263A (pt) | Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto. | |
Rubin et al. | Phase II Study of PALA in Advanced Large Bowel Carcinoma 1, 2 | |
US5525626A (en) | Treating susceptible human malignant tumors with 7-hydroxy-1,2-benzopyrone | |
Handley | Indications and Contraindications | |
RU2000101293A (ru) | Производные бензо(5,6)циклогепта(1,2-в)пиридина для ингибирования фарнезил-протеин-трансферазы | |
Schipper et al. | Polyamine metabolism and programmed cell death in prostatic cancer cells | |
Kröger et al. | 361 Dexverapamil to overcome anthracycline-resistance in advanced breast cancer | |
KR920700636A (ko) | 인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도 | |
Garcia-Giralt et al. | Treatment of stage D hormone resistant carcinoma of the prostate with adriamycin, VM26, cyclophosphamide & 5 FU associated with des | |
Vikran et al. | Accelerated radiation therapy in partly high-grade malignant glioma | |
Dalberg et al. | Randomised trial of long-term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone in patients with early-stage breast cancer treated with breast-conserving surgery | |
Urtasum et al. | A phase I RTOG study of idodeoxyuridine (IUdR) and radiotherapy in the treatment of primary malignant brain | |
Smirnova et al. | Long-term (5-10 year) results of combined treatment of breast cancer patients using gamma-neutron therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |